Abstract: In one aspect, provided herein is a heterologous boost method for inducing an immune response to at least one neoantigen, the method comprising administering to a subject a first boost and subsequently administering to the subject a second boost, wherein the first boost comprises a first oncolytic virus comprising a genome that expresses, in the subject, a first peptide, or the first boost comprises a first oncolytic virus and a second peptide, wherein the second boost comprises a second oncolytic virus comprising a genome that expresses, in the subject, a third peptide, or the second boost comprises a second oncolytic virus and a fourth peptide, wherein the first peptide, the second peptide, the third peptide, and the fourth peptide are each capable of inducing an immune response to at least one neoantigen, and wherein the second oncolytic virus is immunologically distinct from the first oncolytic virus. The subject may have pre-existing immunity to the at least one neoantigen.
Type:
Application
Filed:
March 19, 2020
Publication date:
May 26, 2022
Applicants:
TURNSTONE BIOLOGICS INC., CHILDREN'S HOSPITAL OF EASTERN ONTARIO RESEARCH INSTITUTE INC.
Inventors:
David Stojdl, Justyna KMIECIK, Michael F. BURGESS
Abstract: The present disclosure relates to a sequential boost oncolytic viral immunotherapy and compositions for use in the same. More particularly, the disclosure relates to oncolytic viruses that significantly increase antigen-specific T cell-mediated immune responses when combined in a sequential heterologous boost treatment regimen.
Type:
Application
Filed:
March 19, 2020
Publication date:
May 19, 2022
Applicants:
CHILDREN'S HOSPITAL OF EASTERN ONTARIO RESEARCH INSTITUTE INC., TURNSTONE BIOLOGICS INC.
Inventors:
David Stojdl, Justyna KMIECIK, Michael F. BURGESS